{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:59:34Z","timestamp":1791561574311,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:11:03Z","timestamp":1789225863000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibition in locally advanced, recurrent, and metastatic cutaneous squamous cell carcinoma"],"prefix":"10.1016","author":[{"given":"A. Maria","family":"Vromans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Harrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Constantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Hadfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.09.009_bib0001","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-016-0207-3","article-title":"Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease","volume":"17","author":"Burton","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0002","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.hoc.2024.05.004","article-title":"High-risk non-melanoma skin cancers: biological and therapeutic advances","volume":"38","author":"Lee","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0003","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.currproblcancer.2015.07.005","article-title":"Cutaneous squamous cell carcinoma and related entities: epidemiology, clinical and histological features, and basic science overview","volume":"39","author":"Prieto-Granada","year":"2015","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.11.063","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients","volume":"65","author":"O\u2019Reilly Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0005","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0006","first-page":"170","article-title":"Skin cancer in skin of color","volume":"21","author":"Bradford","year":"2009","journal-title":"Dermatol Nurs"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0007","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm.60846","article-title":"A review of cutaneous squamous cell carcinoma epidemiology, diagnosis, and management","volume":"11","author":"Kabir","year":"2018","journal-title":"Int J Cancer Manag."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0008","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jamadermatol.2019.0032","article-title":"Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women\u2019s Hospital Tumor Classification System for cutaneous squamous cell carcinoma","volume":"155","author":"Ruiz","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cam4.4426","article-title":"Cutaneous squamous cell carcinoma staging may influence management in users: a survey study","volume":"11","author":"Patel","year":"2022","journal-title":"Cancer Med. (Malden, MA)."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0010","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra2206348","article-title":"Squamous-Cell Carcinoma of the Skin","volume":"388","author":"Wysong","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0011","first-page":"284","article-title":"Chemosensitization is not associated with improved adjuvant radiation outcomes for cutaneous squamous cell carcinoma: a dual-center retrospective cohort study","volume":"94","author":"Granger","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0012","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.3390\/cancers16233920","article-title":"The role of radiation, immunotherapy, and chemotherapy in the management of locally advanced or metastatic cutaneous malignancies","volume":"16","author":"Yacoub","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0013","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0014","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.007","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0017","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1002\/cncr.34463","article-title":"A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma","volume":"128","author":"Munhoz","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115121","article-title":"An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma","volume":"214","author":"Pham","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0019","unstructured":"Administration USFD. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. 2018. Accessed September 1, 2026. Available at: https:\/\/www.fda.gov."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0020","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2025.43.16_suppl.6000","article-title":"Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT)","volume":"43","author":"Koyfman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0021","unstructured":"Administration USFD. FDA approves pembrolizumab for cutaneous squamous cell carcinoma. 2020. Accessed September 1, 2026. Available at: https:\/\/www.fda.gov."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0024","unstructured":"Administration USFD. FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma. 2025. Accessed September 1, 2026. Available at: https:\/\/www.fda.gov."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0022","unstructured":"Administration USFD. FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma. 2024. Accessed September 1, 2026. Available at: https:\/\/www.fda.gov."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS9615","article-title":"Phase 2 study of ivonescimab in patients with cutaneous squamous cell carcinoma","volume":"44","author":"Akhave","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib56","unstructured":"Worden, F.P. Pembrolizumab for the Treatment of Locally Advanced and\/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma. ClincalTrials.gov Identifier: NCT06580054. Updated July 29, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT06580054."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib46","unstructured":"Amini, A. Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC. ClincalTrials.gov Identifier: NCT05085496. Updated January 28, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT05085496."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib47","unstructured":"OncoResponse, Inc. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents. ClincalTrials.gov Identifier: NCT06090266. Updated January 7, 2025. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT06090266."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib48","unstructured":"Naing, A. Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic. ClincalTrials.gov Identifier: NCT02721732. Updated July 17, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT02721732."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0025","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma","volume":"393","author":"Rischin","year":"2025","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0026","article-title":"Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies","volume":"29","author":"Cavalieri","year":"2026","journal-title":"Immuno-oncol Technol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib49","unstructured":"Barker, C. A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer. ClincalTrials.gov Identifier: NCT05574101. Updated May 15, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT05574101."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib50","unstructured":"Merck Sharp & Dohme LLC. A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (INTerpath-007). ClincalTrials.gov Identifier: NCT06295809. Updated May 8, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT06295809."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib51","unstructured":"Merck Sharp & Dohme LLC. Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010). ClincalTrials.gov Identifier: NCT06036836. Updated March 19, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT06036836."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib52","unstructured":"In, G.K. A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer. ClincalTrials.gov Identifier: NCT04315701. Updated June 1, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT04315701."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib53","unstructured":"Lowe, M. Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer. ClincalTrials.gov Identifier: NCT04428671. Updated September 14, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT4428671."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib54","unstructured":"Tarhini, A. Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma. ClincalTrials.gov Identifier: NCT04975152. Updated June 25, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT04975152."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib55","unstructured":"Gross, N.D. Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer. ClincalTrials.gov Identifier: NCT06568172. Updated September 1, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT06568172."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.01.180","article-title":"The KEYNOTE-630 trial: a phase 3 study of adjuvant pembrolizumab in high-risk locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)","volume":"118","author":"Schenker","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0028","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO-25-00387","article-title":"Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the De-Squamate study","volume":"43","author":"Ladwa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0029","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0030","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/cancers17101727","article-title":"Radiological, pathological, and surgical outcomes with neoadjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) trial","volume":"17","author":"Lim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0032","doi-asserted-by":"crossref","first-page":"9576","DOI":"10.1200\/JCO.2023.41.16_suppl.9576","article-title":"NEO-CESQ study: neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III\/IV (M0) cutaneous squamous cell carcinoma","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0031","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1038\/s41591-025-03943-w","article-title":"Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial","volume":"31","author":"Breukers","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0033","first-page":"A1","article-title":"774 NeoPOWER: a phase II study of neoadjuvant PD-1 blockade with cemiplimab in high risk localized, locally recurrent and regionally advanced cutaneous squamous cell carcinoma","volume":"11","author":"In","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0034","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers17071172","article-title":"Mutational profile of blood and tumor tissue and biomarkers of response to PD-1 inhibitors in patients with cutaneous squamous cell carcinoma","volume":"17","author":"Chang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0035","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jaad.2020.11.029","article-title":"Anti-tumor necrosis factor therapy is associated with increased in situ squamous cell carcinoma of the skin: a population-based case-control study","volume":"84","author":"Adalsteinsson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0036","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3390\/cancers16183118","article-title":"Current Advances and Challenges in the Management of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients","volume":"16","author":"Li","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0037","first-page":"570","article-title":"Squamous cell carcinoma in solid organ transplant recipients: Review of the literature","volume":"163","author":"Oteiza","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0038","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/DSS.0000000000004680","article-title":"Immunosuppression as an independent risk factor for poor outcomes in cutaneous squamous cell carcinoma: a prospective study","volume":"51","author":"Rosenthal","year":"2025","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0039","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cll.2017.06.003","article-title":"Cutaneous squamous cell carcinoma","volume":"37","author":"Parekh","year":"2017","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0040","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.19218","article-title":"Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies","volume":"37","author":"Lang","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2025.102287","article-title":"PD-1 inhibitor use for skin malignancies in patients with solid organ and bone marrow transplants: Graft rejection, treatment responses, and survival","volume":"93","author":"Parker","year":"2025","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0042","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2025.100699","article-title":"Safety and efficacy results from an open-label phase 1b\/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)","volume":"3","author":"Migden","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0044","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/bjd\/ljaf205","article-title":"Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced\/metastatic cutaneous squamous cell carcinoma","volume":"193","author":"Laimer","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011651","article-title":"Phase 1b\/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors","volume":"13","author":"Milhem","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clindermatol.2026.09.009_bib57","unstructured":"Eroglu, Z. Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma. ClincalTrials.gov Identifier: NCT05070403. Updated July 2, 2026. Accessed September 29, 2026. Available at https:\/\/clinicaltrials.gov\/study\/NCT05070403."}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X2600235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X2600235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:17:50Z","timestamp":1791026270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X2600235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"alternative-id":["S0738081X2600235X"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.009","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibition in locally advanced, recurrent, and metastatic cutaneous squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}